Jobevne Injection
Product Images NDC 83257-009

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Jobevne (NDC 83257-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocon Biologics Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Jobevne Injection 100 mg/4 mL Carton Label (Image 10)

Jobevne Injection 100 mg/4 mL Carton Label (Image 10)
FDA Label Image

Jobevne Injection 400 mg/16 mL Carton Label (Image 11)

Jobevne Injection 400 mg/16 mL Carton Label (Image 11)
FDA Label Image

Figure 1: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study Avf2107g (Image 01)

Figure 1: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study Avf2107g (Image 01)
FDA Label Image

Figure 2: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study mL18147 (Image 02)

Figure 2: Kaplan-meier Curves For Duration Of Survival In Metastatic Colorectal Cancer In Study mL18147 (Image 02)
FDA Label Image

Figure 3: Kaplan-meier Curves For Duration Of Survival In First-line Non-squamous Non-small Cell Lung Cancer In Study E4599 (Image 03)

Figure 3: Kaplan-meier Curves For Duration Of Survival In First-line Non-squamous Non-small Cell Lung Cancer In Study E4599 (Image 03)
FDA Label Image

Figure 4: Kaplan-meier Curves For Progression-free Survival In Metastatic Renal Cell Carcinoma In Study Bo17705 (Image 04)

Figure 4: Kaplan-meier Curves For Progression-free Survival In Metastatic Renal Cell Carcinoma In Study Bo17705 (Image 04)
FDA Label Image

Figure 5: Kaplan-meier Curves For Overall Survival In Persistent, Recurrent, Or Metastatic Cervical Cancer In Study Gog-0240 (Image 05)

Figure 5: Kaplan-meier Curves For Overall Survival In Persistent, Recurrent, Or Metastatic Cervical Cancer In Study Gog-0240 (Image 05)
FDA Label Image

Figure 6: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Stage Iii Or Iv Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Following Initial Surgical Resection In Study Gog-0218 (Image 06)

Figure 6: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Stage Iii Or Iv Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer Following Initial Surgical Resection In Study Gog-0218 (Image 06)
FDA Label Image

Figure 7: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Mo22224 (Image 07)

Figure 7: Kaplan-meier Curves For Investigator-assessed Progression-free Survival In Platinum-resistant Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Mo22224 (Image 07)
FDA Label Image

Figure 8: Kaplan Meier Curves For Progression-free Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Avf4095g (Image 08)

Figure 8: Kaplan Meier Curves For Progression-free Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Avf4095g (Image 08)
FDA Label Image

Figure 9: Kaplan Meier Curves For Overall Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Gog-0213 (Image 09)

Figure 9: Kaplan Meier Curves For Overall Survival In Platinum-sensitive Recurrent Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer In Study Gog-0213 (Image 09)